Autoimmunity / Inflammation

Pipeline :: Asthma

Asthma Therapy

Under our worldwide collaboration with AstraZeneca to discover and develop products for asthma and chronic obstructive pulmonary disorder (COPD), we are developing AZD1419, a novel candidate drug for asthma. AZD1419 utilizes our proprietary second-generation ISS and represents a new strategy for the treatment of allergic respiratory diseases.

AZD1419 therapy is designed to modify the course of disease by changing the basic immune response to environmental allergens, such as house dust and pollens, leading to a prolonged reduction in asthma symptoms. In contrast, the current mainstays of asthma therapy, corticosteroids and bronchodilators, control disease activity or relieve asthma symptoms.

AZD1419 has been selected as the lead candidate to enter formal clinical development based on preclinical studies conducted by Dynavax and AstraZeneca. These studies showed that AZD1419 is capable of producing long lasting disease-modifying effects in a mouse model of atopic asthma.

In October 2011, we amended our agreement with AstraZeneca for the development of AZD1419. Development expenses will be fully funded by AstraZeneca through Phase 2a. If AstraZeneca chooses to advance the program following completion of Phase 2a, AstraZeneca will retain its rights to develop the candidate therapy and to commercialize the resulting asthma product. Dynavax is eligible to receive royalties on worldwide sales of approved products and has the option to co-promote the product in the United States.

Commercial Opportunity

According to the World Health Organization, asthma affects 300 million people worldwide. Asthma is a chronic disease of the lungs and is caused primarily by allergic inflammation of the airways. In addition, 210 million people worldwide are affected by COPD, a term used to describe chronic lung diseases that limit airflow in the lungs. Analysts estimate the current worldwide market opportunity for asthma and COPD therapies to be over $15 billion annually.